BioCentury
ARTICLE | Financial News

Cardiorentis raises CHF60M in series B

January 12, 2016 2:45 AM UTC

Cardiorentis AG (Zug, Switzerland) raised CHF60 million ($60.1 million) in a series B round. Spokesperson Kellie Walsh May said three "ultra-high net worth European investors" participated, but declined to name them.

The company expects results this half of a Phase III trial of lead candidate ularitide ( ULA01) to treat acute decompensated heart failure (ADHF), and plans to submit an NDA to FDA in 2H16. The IV infusion of a chemically synthesized form of the naturally occurring natriuretic peptide urodilatin has Fast Track designation from FDA. ...